Shares of Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) were up 10.9% on Friday . The company traded as high as $2.60 and last traded at $2.55. Approximately 748,700 shares traded hands during trading, an increase of 117% from the average daily volume of 345,200 shares. The stock had previously closed at $2.30.

A number of analysts have weighed in on AST shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Asterias Biotherapeutics in a research note on Monday, October 2nd. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $8.94.

The stock has a market cap of $135.38, a P/E ratio of -3.92 and a beta of 1.30.

TRADEMARK VIOLATION NOTICE: “Asterias Biotherapeutics (AST) Trading Up 10.9%” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/asterias-biotherapeutics-ast-trading-up-10-9/1804700.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.